Institutional members access full text with Ovid®

Share this article on:

Optimization of Continuous Infusion of Piperacillin–Tazobactam in Children With Fever and Neutropenia

Delvallée, Mélanie MD*†; Mazingue, Françoise MD†‡; Abouchahla, Wadi MD†‡; Delebarre, Mathilde MD†‡; Wallet, Frédéric MD*†; Courcol, René MD, PhD*†; Kipnis, Eric MD, PhD†§¶; Dessein, Rodrigue MD, PhD*†¶

The Pediatric Infectious Disease Journal: September 2013 - Volume 32 - Issue 9 - p 962–964
doi: 10.1097/INF.0b013e318298dfb8
Antimicrobial Reviews

The study through Monte Carlo simulation of β-lactam pharmacokinetic/pharmacodynamic target attainment and determination of subsequent serum concentrations of piperacillin–tazobactam administered through continuous infusion to children treated for fever and neutropenia shows that 400 mg/kg/day has the highest probability of target attainment against Pseudomonas aeurginosa in our oncology ward compared with the standard regimen of 300 mg/kg/day.

From the *Laboratoire de Bactériologie Hygiène, Institut de Microbiologie, Centre de Biologie Pathologie; Université Lille Nord de France; Hématologie Pédiatrique, Hôpital Jeanne de Flandres; §Réanimation Chirurgicale, Hôpital Claude Huriez, CHRU de Lille; and Pseudomonas aeruginosa Host-pathogen Translational Research Group, Lille School of Medicine, UDSL, Lille North of France University, Lille, France.

Accepted for publication March 24, 2013.

This work was funded by a grant from the Ministère en charge de la Santé.

R.D. was the principal investigator and takes primary responsibility for the article. F.M., W.A. and Ma.D. recruited the patients and gave correction to the article. Mé.D. performed the laboratory work and Monte Carlo simulation. F.W. participated in the interpretation of the results. R.C. helped with financial support. E.K. and R.D. interpreted the results and wrote the article. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Rodrigue Dessein, MD, PhD, Laboratoire de Bactériologie Hygiène, Institut de Microbiologie, Centre de Biologie Pathologie, CHRU Lille, Univ Lille Nord de France, F-59000 Lille, France. E-mail: rodrigue.dessein@chru-lille.fr.

© 2013 by Lippincott Williams & Wilkins, Inc.